

Notice Regarding Partial Corrections to the Notice of Convocation of the 21st Term Annual Shareholders Meeting

TOKYO, June 10, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) hereby announces that certain corrections have been made to the matters described in the “Notice of Convocation of the 21st Term Annual Shareholders Meeting.” We sincerely apologize for any inconvenience caused and provide details of the corrections as follows.

Details of the Corrections

(Amended portions are underlined.)

Amendment to page 75 of the “Notice of Convocation of the 21st Term Annual Shareholders Meeting”

[Chart 4. Targets and actual results of respective key performance indicators, and share delivery rate (the ratio of the number of shares actually delivered to the basic points) of stock compensation (medium- to long-term incentive remuneration) for Directors who are not Audit & Supervisory Committee Members (excluding outside Directors) which final year of the assessment period is the 21st term business year]

<Before the Amendment>

Key performance indicators	(omitted)	(omitted)	(omitted)	Actual results	(omitted)
TSR (1) (Comparison with TOPIX growth rate)	(omitted)	(omitted)	(omitted)	TOPIX growth rate: <u>141.0%</u> Growth rate of the Company's TSR: <u>197.0%</u>	(omitted)

<After the Amendment>

Key performance indicators	(omitted)	(omitted)	(omitted)	Actual results	(omitted)
TSR (1) (Comparison with TOPIX growth rate)	(omitted)	(omitted)	(omitted)	TOPIX growth rate: <u>197.0%</u> Growth rate of the Company's TSR: <u>141.0%</u>	(omitted)